** Online telehealth company Hims and Hers Health HIMS.N missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs
** Median PT of 14 brokerages covering stock is $48 - LSEG data
** Co's shares were down 12.7% at $55.31 premarket
ANALYSTS POSITIVE ON LONG TERM GROWTH
** Jefferies ("hold" PT: $51) expects continued stock volatility in near term; adds, "that said, we have a positive view on HIMS's strategies to introduce healthcare personalization and the rollout of new offerings"
** BTIG ("buy," PT: $85) says slow-down in commercial GLP-1s subscriptions is likely temporary, expects sequential growth; adds, "GLP-1 volumes will transition to shorter duration prescriptions (90 days) and we still view the obesity health market as being robust"
** Canaccord Genuity ("buy," PT: $68) says "...the roll-out of new treatments, continued investment in personalization capabilities, and an expanding international presence, we remain positive on Hims' long-term growth outlook"
** Leerink Partners ("market perform" PT: $43) says "HIMS's near-term performance will likely be most closely tied to GLP-1s/weight management developments, especially the pacing of international launches in Canada and in conjunction with other international expansion efforts"
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。